PureTech Health plc
NASDAQ:PRTC · NASDAQ Global Market
+$0.45 today
Vol 0.00M · Avg 0.01M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$110.0M -495.9% | $27.8M +142.3% | -$65.7M -77.2% | -$37.1M +40.9% | -$62.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $3.4M -6.0% | $3.6M -27.6% | $4.9M -44.5% | $8.9M +22.0% | $7.3M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 +100.0% | -$70.1M +37.7% | -$112.6M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $8.2M -64.0% | $22.9M +417.6% | $4.4M -70.0% | $14.7M +5.4% | $13.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$3.1M +69.4% | -$10.2M -158.4% | $17.5M +10.1% | $15.9M +1748.9% | $861.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$236.6K -137.6% | $629.0K -93.5% | $9.8M +226.1% | -$7.7M -1153.5% | -$617.0K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 +100.0% | -$103.0K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$1.0M +89.4% | -$9.7M -352.2% | $3.8M -82.6% | $22.0M +164.2% | $8.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$1.9M -59.5% | -$1.2M -129.8% | $3.9M +142.3% | $1.6M +124.0% | -$6.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $16.2M +109.1% | -$178.3M -165.8% | -$67.1M +39.6% | -$111.1M -2100.4% | -$5.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$85.3M +36.5% | -$134.4M -26.9% | -$105.9M +40.8% | -$178.8M -13.0% | -$158.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$6.0K +45.4% | -$11.0K +95.5% | -$245.0K +88.7% | -$2.2M +61.6% | -$5.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $269.6K +100.3% | -$106.0M -668.8% | -$13.8M +32.6% | -$20.4M -6467.6% | $321.0K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$85.3M +72.5% | -$309.6M -58.2% | -$195.7M +27.2% | -$268.7M -53646.6% | -$500.0K | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $148.4M -77.4% | $656.2M +136.2% | $277.9M +51.3% | $183.7M -15.8% | $218.1M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $49.1K -80.7% | $255.0K -70.5% | $865.0K +107.9% | $416.0K +102.8% | -$14.9M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $63.4M -73.7% | $240.9M +249.2% | $69.0M +164.3% | -$107.2M -154.3% | $197.4M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$3.4M -1.7% | -$3.3M -949.4% | $393.0K -82.3% | $2.2M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $106.2K -88.1% | $895.0K -22.4% | $1.2M +247.3% | $332.0K -99.1% | $38.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$2.1M +98.1% | -$107.6M -447.4% | -$19.6M +25.8% | -$26.5M -98.7% | -$13.3M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$4.4M -104.7% | $93.1M -6.9% | $100.0M +2558.2% | -$4.1M -112.0% | $33.8M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$6.3M +62.6% | -$17.0M -121.7% | $78.1M +362.0% | -$29.8M -231.2% | $22.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $19.8K | $0 | $0 | $0 +100.0% | -$1.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$28.2M -131.5% | $89.6M +117.3% | $41.2M +113.0% | -$315.8M -610.8% | $61.8M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$85.3M +36.5% | -$134.4M -26.6% | -$106.2M +41.3% | -$181.0M -10.4% | -$163.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.85B
Solid Biosciences Inc.
NASDAQ:SLDB
$590.17M
Neurogene Inc.
NASDAQ:NGNE
$496.34M
Autolus Therapeutics plc
NASDAQ:AUTL
$409.86M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$350.94M
Benitec Biopharma Inc.
NASDAQ:BNTC
$316.28M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$304.14M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$271.13M
Quantum-Si incorporated
NASDAQ:QSI
$193.17M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
SEC Filings
Recent regulatory filings
No filings found.
Does PRTC generate free cash flow?
PureTech Health plc (PRTC) generated -$85,335,950.00 of free cash flow in fiscal 2025.
How much operating cash flow does PRTC produce?
Operating cash flow was -$85,329,940.00, before capital expenditures of $6,010.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.